Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Xvivo Perfusion Aktiebolag
AB
Active
Org 5565610424
Entreprenörsstråket 10, 431 53
Mölndal
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 1998
50-99 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Xvivo Perfusion Aktiebolag
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
130M
260M
391M
521M
134M
2020
161M
2021
244M
2022
277M
2023
453M
2024
EBITDA
SEK millions
0M
20M
40M
60M
81M
-42M
2020
-7M
2021
24M
2022
-28M
2023
70M
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
134 122
161 287
243 737
276 937
453 072
Staff expenses
—
—
—
—
—
EBITDA
−41 604
−7 360
23 927
−27 853
69 911
Depreciation & amort.
—
—
—
—
—
EBIT
−41 604
−7 360
23 927
−27 853
69 911
Net financials
−10 609
6 475
19 982
25 149
19 269
Profit before tax
−48 013
−885
43 909
−2 704
123 437
Tax
9 577
−181
−9 177
−2 360
−24 872
Net profit
−38 436
−1 066
34 732
−5 064
98 565
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
1 080 758
1 440 580
1 565 528
1 869 030
1 932 530
Equity
1 000 817
1 246 317
1 341 567
1 721 754
1 828 078
Long-term debt
40 150
124 522
137 130
68 766
6 215
Short-term debt
38 480
68 242
85 457
63 554
82 525
Total debt
78 630
192 764
222 587
132 320
88 740
Financial ratios
5-year trend
EBITDA margin
15.4%
This company
15.8%
Market median
+3% vs market
2020
2024
Equity ratio
94.6%
This company
38.2%
Market median
+148% vs market
2020
2024
Return on equity
5.4%
This company
18.4%
Market median
-71% vs market
2020
2024
Net profit margin
21.8%
This company
8.1%
Market median
+169% vs market
2020
2024
Asset turnover
0.23×
This company
1.12×
Market median
-79% vs market
2020
2024
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Xvivo Perfusion Aktiebolag
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
